Germline BRCA2 mutation pancreatic adenocarcinoma

Abstract

Pancreatic adenocarcinoma is one of the most challenging malignancies. Its surgical resection is regarded as the only potential curative treatment. However, most patients present with advanced stages, associated with very poor prognosis. Germline BRCA1 and BRCA2 (BRCA1/2) mutations account for few advanced pancreatic adenocarcinomas and thus present as disease-specific entities. Cancers harboring BRCA1/2 mutations are relatively more chemosensitive and have exhibited survival benefits with platinum-containing combination treatments. FOLFIRINOX has been evaluated in various trials and is a well-established first-line chemotherapy for metastatic pancreatic cancer in patients with good performance status. Here, we report the case of a patient with germline BRCA2-mutation pancreatic adenocarcinoma who exhibited a good response to modified FOLFIRINOX, achieving an 18-month complete response.